Cancer-Focused Biotech Co. Leads 2 IPOs Netting $561M Total

Law360 (July 16, 2020, 3:41 PM EDT) -- A cancer-focused biotechnology company and a specialty insurer debuted to receptive public markets on Thursday after pricing initial public offerings that raised $561 million combined under guidance from four law firms, joining an IPO stampede that shows no signs of easing.

Relay Therapeutics Inc., advised by Goodwin Procter LLP, led the pair of deals with a $400 million IPO that sold 20 million shares at $20, above its range of $18 to $19. Cambridge, Massachusetts-based Relay also raised its offering size from initial plans to sell 14.7 million shares.

Trean Insurance Group Inc., advised by Skadden Arps Slate Meagher & Flom...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!